Valentine Odirachukwumma Nwanelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentine Odirachukwumma Nwanelo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chidinma Pamela Ononiwu
Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria
1 shared publication Chigozie Paul Odo
Department of Biochemistry, University of Nigeria, Nsukka, 410001, Enugu, Nigeria
1 shared publication- Chioma Assumpta Anosike
Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria
1 shared publication - Christian Chijioke Amah
Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria
1 shared publication - Chukwubuikem Stephen Nnemolisa
Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria
1 shared publication Dionysius Obinna Osuji
Department of Biochemistry, University of Nigeria, Nsukka, 410001, Enugu, Nigeria
1 shared publication
Latest Publications
- Open Access
- 18 November 2024
- Published by Springer Nature in Laboratory Animal Research
- Vol. 40 (1) , 1-26
Cleistopholis patens root bark extract exerts cardioprotective effect against doxorubicin-induced myocardial toxicity in rats
Background: Myocardial Infarction still persists as the most prevalent cardiovascular disease and is a top cause of morbidity and mortality in doxorubicin treated cancer patients. This study evaluated the prophylactic effect of the ethanol root bark extract of Cleistopholis patens (ERBECP) against doxorubicin-induced myocardial infarction in wistar rats. Extraction, preliminary phytochemical analysis, acute toxicity study and body weight (b.w.) of ERBECP were achieved using standard methods. Phyto-constituents in ERBECP were indentified using Gas Chromatography-Mass Spectrometry (GC–MS) technique. Thirty (30) male albino Wistar rats of average b.w. ranging between 100 and 130 g were divided into six groups of five rats each. Groups I, II and III served as normal, doxorubicin (DOX) and standard (Vasoprin 150 mg/kg b.w) controls respectively, while groups IV, V and VI were orally pre-treated with the extract (200, 400 and 600 mg/kgb.w) for two weeks prior to intraperitoneal induction of cardiotoxicity with DOX (20 mg/kg bw) on day 14. Results: Disturbances in serum cardiac function bio-markers such as; Cardiac Troponin-I (CTnI), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT). Lipid profile markers such as; Total cholesterol (TC), Triacylglycerol (TAG), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL). Oxidative stress markers such as; Malondialdehyde (MDA), Superoxide Dismutase (SOD), Catalase (CAT), Glutathione (GSH) confirmed the induction of myocardial infarction. Histological assessment of heart tissues was performed to validate biochemical results. The GC–MS analysis of ERBECP identified a total of 69 compounds. Safety profile of the aqueous extract was safe for the animals up to the highest dose of 5000 mg/kg b.w. Pre-treatment of DOX group with ERBECP could significantly increase the b.w. compared to the DOX-treated group during the experimental period of 2 weeks. There were significant (p < 0.05) alterations in the levels of CTnI, CK, LDH, AST, ALT and lipid profile indices in the DOX control rats. Also, significant (p < 0.05) increase was observed in MDA and decrease in SOD, CAT and GSH in the DOX control rats. However, administration of the extract significantly (p < 0.05) normalized these alterations and reversed the architectural changes in the heart. The 69 compounds were screened against the target protein (CBR1); we identified seven hits based on the docking score and interactions with the active site residues. All the C. patens constituents had MW (g/mol) less than 500, HBA < 10 and HBD not more than 5. Apart, 9-Octadecenoic acid (Z)-, 2,3-dihydroxy propyl ester and Estra-1,3,5(10)-trien-17. beta. -ol, all the constituents had LD50 lower than 2000 mg/kg. Conclusions: The findings reveals ERBECP demonstrated promising potential and can be exploited in the development novel cardiac therapeutic agents.
- 18 November 2024
- Published by Springer Nature in Laboratory Animal Research
- Vol. 40 (1) , 1-26
Open AccessCleistopholis patens root bark extract exerts cardioprotective effect against doxorubicin-induced myocardial toxicity in rats
Background: Myocardial Infarction still persists as the most prevalent cardiovascular disease and is a top cause of morbidity and mortality in doxorubicin treated cancer patients. This study evaluated the prophylactic effect of the ethanol root bark extract of Cleistopholis patens (ERBECP) against doxorubicin-induced myocardial infarction in wistar rats. Extraction, preliminary phytochemical analysis, acute toxicity study and body weight (b.w.) of ERBECP were achieved using standard methods. Phyto-constituents in ERBECP were indentified using Gas Chromatography-Mass Spectrometry (GC–MS) technique. Thirty (30) male albino Wistar rats of average b.w. ranging between 100 and 130 g were divided into six groups of five rats each. Groups I, II and III served as normal, doxorubicin (DOX) and standard (Vasoprin 150 mg/kg b.w) controls respectively, while groups IV, V and VI were orally pre-treated with the extract (200, 400 and 600 mg/kgb.w) for two weeks prior to intraperitoneal induction of cardiotoxicity with DOX (20 mg/kg bw) on day 14. Results: Disturbances in serum cardiac function bio-markers such as; Cardiac Troponin-I (CTnI), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT). Lipid profile markers such as; Total cholesterol (TC), Triacylglycerol (TAG), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL). Oxidative stress markers such as; Malondialdehyde (MDA), Superoxide Dismutase (SOD), Catalase (CAT), Glutathione (GSH) confirmed the induction of myocardial infarction. Histological assessment of heart tissues was performed to validate biochemical results. The GC–MS analysis of ERBECP identified a total of 69 compounds. Safety profile of the aqueous extract was safe for the animals up to the highest dose of 5000 mg/kg b.w. Pre-treatment of DOX group with ERBECP could significantly increase the b.w. compared to the DOX-treated group during the experimental period of 2 weeks. There were significant (p < 0.05) alterations in the levels of CTnI, CK, LDH, AST, ALT and lipid profile indices in the DOX control rats. Also, significant (p < 0.05) increase was observed in MDA and decrease in SOD, CAT and GSH in the DOX control rats. However, administration of the extract significantly (p < 0.05) normalized these alterations and reversed the architectural changes in the heart. The 69 compounds were screened against the target protein (CBR1); we identified seven hits based on the docking score and interactions with the active site residues. All the C. patens constituents had MW (g/mol) less than 500, HBA < 10 and HBD not more than 5. Apart, 9-Octadecenoic acid (Z)-, 2,3-dihydroxy propyl ester and Estra-1,3,5(10)-trien-17. beta. -ol, all the constituents had LD50 lower than 2000 mg/kg. Conclusions: The findings reveals ERBECP demonstrated promising potential and can be exploited in the development novel cardiac therapeutic agents.
- Open Access
- 28 September 2023
- Published by Springer Nature in Research Square
An investigation of the phytochemical richness of fresh Musa paradisiaca L. (plantain) stem juice and its anticonvulsant potential on pentylenetetrazole (PTZ)-challenged rats
This study was aimed at determining the therapeutic value of fresh Musa paradisiaca L. (MP) stem juice as a potential treatment for epileptic convulsions using a pentylenetetrazole (PTZ)-induced seizure model in rats. Six groups of albino rats (n = 4) were involved in the study. Group I was treated with normal saline (p.o), while group II was untreated and group III received diazepam (4 mg/kg, p.o). Group IV, V and VI received 50, 75 and 100% v/v oral dose of MP stem juice, respectively). The treatment lasted for 10 days, followed by PTZ (85 mg/kg b.w, i.p) administration 60 min later. Lethality test and phytochemical screening were conducted. The rats were closely watched and meticulously monitored for seizure manifestations/episodes with the aid of a stop watch. From the results, the MP stem juice up to 100% (v/v) was safe in mice and numerous bioactive compounds were found with phenols being the most abundant (9.46 ± 0.03 mg/g), followed by alkaloids (5.54 ± 0.98 mg/g) and flavonoids (4.27 ± 1.23 mg/g). For the seizure manifestation, three intermittent seizures (episodes 1, 2 and 3) were observed and the stem juice (75 and 100% v/v) significantly (p < 0.05) increased the latency periods of episode 1 tonic and clonic seizures. The stem juice at 50% (v/v) delayed the onset of episode 2 seizures for over 10 minutes more than the untreated group. The groups that received 75 and 100% (v/v) of the stem juice did not experience seizures during the episode 2 as seen in episode 1. The standard and the test groups did not experience seizure during the episode 3. The findings of this study have demonstrated that the fresh MP stem juice could prevent convulsions by increasing the latencies and decreasing relatively the durations of seizures in PTZ-challenged rats. This study, however, provides the pharmacological evidence for the folk claim behind the use of Musa paradisiaca stem juice to manage epileptic convulsions or seizure disorders.
- 28 September 2023
- Published by Springer Nature in Research Square
Open AccessAn investigation of the phytochemical richness of fresh Musa paradisiaca L. (plantain) stem juice and its anticonvulsant potential on pentylenetetrazole (PTZ)-challenged rats
This study was aimed at determining the therapeutic value of fresh Musa paradisiaca L. (MP) stem juice as a potential treatment for epileptic convulsions using a pentylenetetrazole (PTZ)-induced seizure model in rats. Six groups of albino rats (n = 4) were involved in the study. Group I was treated with normal saline (p.o), while group II was untreated and group III received diazepam (4 mg/kg, p.o). Group IV, V and VI received 50, 75 and 100% v/v oral dose of MP stem juice, respectively). The treatment lasted for 10 days, followed by PTZ (85 mg/kg b.w, i.p) administration 60 min later. Lethality test and phytochemical screening were conducted. The rats were closely watched and meticulously monitored for seizure manifestations/episodes with the aid of a stop watch. From the results, the MP stem juice up to 100% (v/v) was safe in mice and numerous bioactive compounds were found with phenols being the most abundant (9.46 ± 0.03 mg/g), followed by alkaloids (5.54 ± 0.98 mg/g) and flavonoids (4.27 ± 1.23 mg/g). For the seizure manifestation, three intermittent seizures (episodes 1, 2 and 3) were observed and the stem juice (75 and 100% v/v) significantly (p < 0.05) increased the latency periods of episode 1 tonic and clonic seizures. The stem juice at 50% (v/v) delayed the onset of episode 2 seizures for over 10 minutes more than the untreated group. The groups that received 75 and 100% (v/v) of the stem juice did not experience seizures during the episode 2 as seen in episode 1. The standard and the test groups did not experience seizure during the episode 3. The findings of this study have demonstrated that the fresh MP stem juice could prevent convulsions by increasing the latencies and decreasing relatively the durations of seizures in PTZ-challenged rats. This study, however, provides the pharmacological evidence for the folk claim behind the use of Musa paradisiaca stem juice to manage epileptic convulsions or seizure disorders.